Cnbc
@cnbc·4.2M subscribers·16.1K videos
BioMarin CEO: Rare Treatments, High Costs | Mad Money | CNBC
Posted
May 1, 2017
Views
2,536
Likes
15
Comments
1
Engagement
0.63%
May 1, 2017
2,536
15
1
0.63%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
BioMarin just got good news from the FDA for a treatment of an ultra-rare disorder. But with a price tag of $702,000 a year, is a drug price debate waiting in the wings? Jim Cramer spoke with the CEO for his take.
» Subscribe to CNBC
» Watch more Mad Money here
» Read more about BioMarin here
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Read the latest news
Watch full episodes
Follow Mad Money on Twitter
Like Mad Money on Facebook
Follow Cramer on Twitter
Connect with CNBC News Online!
Visit CNBC.com
Find CNBC News on Facebook
Follow CNBC News on Twitter
Follow CNBC News on Google+
Follow CNBC News on Instagram
BioMarin CEO: Rare Treatments, High Costs | Mad Money | CNBC
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
